Back to results
US 8,486,693 B2Granted
Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
AssigneeBellicum Pharmaceuticals, Inc.
InventorsDongsu Park, David Spencer, Natalia Lapteva
Life of this patent
Estimating the term…
Abstract
Modified antigen presenting cells provided herein have improved lifespan and immunogenicity compared to unmodified antigen presenting cells, and are useful for immunotherapy. The modified antigen presenting cells express an altered protein kinase, referred to herein as “Akt.” The altered Akt associates with the cell membrane with greater frequency than unaltered Akt, and is referred to herein as “membrane-targeted Akt.”
Claims24
A method for preparing a modified dendritic cell, which comprises:
- transferring a polynucleotide into a dendritic cell, wherein the polynucleotide encodes a membrane-targeted Akt protein comprising a dual acylation region and a mammalian Akt region, wherein the mammalian Akt region comprises the amino acid sequence of SEQ ID NO:
- 6, wherein the membrane-targeted Akt protein is expressed in the dendritic cell and the modified dendritic cell survives longer than dendritic cells that do not express the protein.
A method for preparing a modified dendritic cell, which comprises:
- transferring a polynucleotide into a dendritic cell, wherein the polynucleotide encodes a membrane-targeted Akt protein comprising a dual acylation region and a mammalian Akt region, wherein the mammalian Akt region consists of the amino acid sequence of SEQ ID NO:
- 6, wherein the membrane-targeted Akt protein is expressed in the dendritic cell and the modified dendritic cell survives longer than dendritic cells that do not express the protein.
Dependencies are inferred from the claim text.